Literature DB >> 30633329

Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real-life practice.

M Tauber1,2, P A Apoil3, C Richet1, J Laurent4, G De Bonnecaze5, E Mouchon5, M Cassagne6, M C Marguery1, S Hegazy1, M P Konstantinou1, M Severino1, C Uthurriague1, F Giordano-Labadie1, A Didier7, C Paul1,2.   

Abstract

Entities:  

Year:  2019        PMID： 30633329     DOI： 10.1111/bjd.17629

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  6 in total

1.  Impact on health-related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate-to-severe atopic dermatitis.

Authors:  Marco Miniotti; Giulia Lazzarin; Michela Ortoncelli; Luca Mastorino; Simone Ribero; Paolo Leombruni
Journal:  Dermatol Ther       Date:  2022-03-03       Impact factor: 3.858

2.  Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice.

Authors:  Dong Hyek Jang; Seok Jae Heo; Hye Jung Jung; Mi Yeon Park; Seong Jun Seo; Jiyoung Ahn
Journal:  J Clin Med       Date:  2020-06-24       Impact factor: 4.241

Review 3.  A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis.

Authors:  Masahiro Kamata; Yayoi Tada
Journal:  JID Innov       Date:  2021-07-30

4.  Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.

Authors:  D O'Kane; L Davis; M Ardern-Jones; P Laws; L Shaw; M Cork; S Velangi; H L Cooper; R Hudson; A B Smith; R Rout
Journal:  Ulster Med J       Date:  2021-07-08

5.  Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports.

Authors:  S Ferrucci; M Romagnuolo; L Angileri; E Berti; S Tavecchio
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-08       Impact factor: 9.228

6.  Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience.

Authors:  Silvia Ferrucci; Giovanni Casazza; Luisa Angileri; Simona Tavecchio; Francesca Germiniasi; Emilio Berti; Angelo Valerio Marzano; Giovanni Genovese
Journal:  J Clin Med       Date:  2020-03-13       Impact factor: 4.241
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.